Protein Array Platform for Rheumatoid Arthritis Diagnosis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic tests for rheumatoid arthritis (RA) rely heavily on cyclic citrullinated peptide (CCP) assays, which lack specificity and sensitivity, particularly in distinguishing RA from other autoimmune diseases.
Innovation Solution
Development of a protein array platform that enables the simultaneous modification and analysis of multiple proteins for immunogenicity, identifying novel citrullinated antigens such as Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1), and stanniocalcin-2 (STC2), which show higher reactivity in RA patients.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If cyclic citrullinated peptide (CCP) assays are used for RA diagnosis, then the diagnostic process is simple and quick, but the sensitivity and specificity are insufficient particularly in distinguishing RA from other autoimmune diseases
Solution Approach 1:
The patent segments the diagnostic approach by dividing the protein analysis into individual recombinant proteins expressed in E. coli, each tested separately in ELISA assays. This segmentation allows for precise identification of specific autoantibody targets while maintaining manageable experimental complexity through modular testing of individual proteins rather than analyzing complex protein mixtures simultaneously.
Solution Approach 2:
The patent employs a universal ELISA platform that can test multiple different recombinant proteins using the same basic assay methodology. The ELISA technique serves multiple functions: detecting autoantibodies against different citrullinated proteins, quantifying antibody levels, and providing a standardized approach across various protein targets, thereby improving diagnostic precision without proportionally increasing operational complexity.
2Productivity
If multiple proteins are modified and analyzed individually through traditional methods, then each protein can be thoroughly characterized, but the process is time-consuming and labor-intensive
Solution Approach 1:
The patent applies preliminary action by pre-modifying the recombinant proteins with citrulline residues before conducting the ELISA assays. The proteins are expressed, purified, and citrullinated in advance, allowing the actual diagnostic testing to proceed efficiently without time-consuming modifications during the assay process. This preliminary preparation enables high-throughput analysis of multiple proteins.
Solution Approach 2:
The E. coli expression system serves itself by naturally producing the recombinant proteins with appropriate post-translational modifications. The system self-manages protein folding, modification, and secretion, reducing the need for complex external intervention in protein preparation and enabling straightforward purification and analysis.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The platform achieves improved sensitivity and specificity in diagnosing RA, with the identified antigens demonstrating 82% sensitivity for CCP+ samples and 22% sensitivity for CCP- samples at 95% specificity, offering potential for more accurate RA diagnosis and understanding of disease pathogenesis.
Implementation Method 1
Citrullination is a post translational modification (PTM) that converts arginine to citrulline catalyzed by peptidyl arginine deiminase (PAD)
Implementation Method 2
Anti-citrullinated protein antibodies (ACPA) have been specifically detected in rheumatoid arthritis (RA) patients
Data Source
AI summary
Compositions and methods for detection of anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis (RA) patients. Patient samples known or suspected of containing ACPAs were probed against citrullinated proteins, and antibody responses to 190 citrullinated proteins in 20 RA patients were investigated. Unique antibody reactivity patterns in both clinical anti-cyclic citrullinated peptide assay positive (CCP+) and negative (CCP−) RA patients were observed. At individual antigen levels, six novel antibody/antigen complexes were discovered and validated against specific citrullinated antigens (Myelin Basic Protein (MBP), osteopontin (SPP1), flap endonuclease (FEN1), insulin like growth factor binding protein 6 (IGFBP6), insulin like growth factor I (IGF1) and stanniocalcin-2 (STC2)) in RA patients. Identification of immune-dominant epitope(s) for citrullinated MBP was also performed. The identified biomarkers have high specificity, especially MBP.